Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy

Chronic kidney disease (CKD) before treatment and renal function decline during treatment are common in elderly patients receiving hypomethylating agents (HMAs) and venetoclax (VEN). This retrospective multicenter study of 130 newly diagnosed older acute myeloid leukemia (AML) patients evaluated the prognostic impact of renal function before and during the first treatment cycle. A total of 56 patients (43%) had CKD, and 49 (38%) developed acute kidney injury (AKI) during treatment. AKI occurrence was associated with laboratory tumor lysis syndrome (LTLS). CKD before treatment showed a trend towards a lower overall response rate (ORR, OR 0.5, <i>p</i> = 0.07) in multivariable analysis (MVA) and inferior relapse-free survival (RFS, HR 2.16, <i>p</i> = 0.06) in univariate analysis (UVA), but not MVA (RFS, HR 1.93, <i>p</i> = 0.15). CKD did not affect overall survival (OS) or event-free survival (EFS). AKI during HMA/VEN therapy was associated with significantly higher 30-day and 60-day mortality rates and emerged as an independent prognostic factor for inferior OS (HR 1.86, <i>p</i> = 0.01) and EFS (HR 1.81, <i>p</i> = 0.007). RFS did not differ significantly by AKI status. Sepsis was a more frequent cause of death in patients with vs. without AKI (33% vs. 5%). In conclusion, kidney function is a key prognostic factor in HMA/VEN-treated patients, warranting further study on treatment adjustments and supportive care.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2025-09-13
DOI
https://doi.org/10.3390/cancers17182993
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy

Andreas Voß, Martin Grießhammer, Kai Wille, Ulrich Germing et al.
Cancers
Acute Myeloid Leukemia Research
article

Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy

Andreas Voß, Martin Grießhammer, Kai Wille, Ulrich Germing, Bernhard M. W. Schmidt, Krischan Braitsch, Franziska Modemann, Christoph Röllig, Jan Moritz Middeke, Lars Bullinger, Gernot Beutel, Heinz Kirchen, Laura K. Schmalbrock, Michael Heuser, Konstanze Döhner, Elisabeth Koller, Felicitas Thol, Stephan Kaun, Katharina S. S. Götze, Jan Braess, Rabia Shahswar, Ulrich Kaiser, Razif Gabdoulline, Walter Fiedler, Hartmut Döhner, Peter Reimer, Florian Heinrich Heidel, Frank Hartmann, Anke K. Bergmann, Jürgen Krauter, Martin Wichmann, Katja Krüger, Daniel Föhring
article en

Abstract

Chronic kidney disease (CKD) before treatment and renal function decline during treatment are common in elderly patients receiving hypomethylating agents (HMAs) and venetoclax (VEN). This retrospective multicenter study of 130 newly diagnosed older acute myeloid leukemia (AML) patients evaluated the prognostic impact of renal function before and during the first treatment cycle. A total of 56 patients (43%) had CKD, and 49 (38%) developed acute kidney injury (AKI) during treatment. AKI occurrence was associated with laboratory tumor lysis syndrome (LTLS). CKD before treatment showed a trend towards a lower overall response rate (ORR, OR 0.5, <i>p</i> = 0.07) in multivariable analysis (MVA) and inferior relapse-free survival (RFS, HR 2.16, <i>p</i> = 0.06) in univariate analysis (UVA), but not MVA (RFS, HR 1.93, <i>p</i> = 0.15). CKD did not affect overall survival (OS) or event-free survival (EFS). AKI during HMA/VEN therapy was associated with significantly higher 30-day and 60-day mortality rates and emerged as an independent prognostic factor for inferior OS (HR 1.86, <i>p</i> = 0.01) and EFS (HR 1.81, <i>p</i> = 0.007). RFS did not differ significantly by AKI status. Sepsis was a more frequent cause of death in patients with vs. without AKI (33% vs. 5%). In conclusion, kidney function is a key prognostic factor in HMA/VEN-treated patients, warranting further study on treatment adjustments and supportive care.

CancersVol. 17(18)
Carl von Ossietzky Universität Oldenburg (DE), Universität Hamburg (DE), Medizinische Hochschule Hannover (DE), Krankenhaus der Barmherzigen Brüder Trier (DE), Elisabeth-Krankenhaus Essen (DE), Hanusch Hospital (AT), St. Bernward Krankenhaus (DE), University Medical Center Hamburg-Eppendorf (DE), Klinikum Oldenburg (DE), Klinikum Braunschweig (DE), Krankenhaus Barmherzige Brüder (DE), Universitätsklinikum Würzburg (DE), Klinikum Lippe (DE), Kliniken Essen-Mitte (DE), Klinikum Bremen-Mitte (DE), University Hospital Ulm (DE), Johannes Wesling Klinikum Minden (DE), Hochschule für Technik und Wirtschaft Dresden – University of Applied Sciences (DE), Heinrich Heine University Düsseldorf (DE), Franklin University (US), Technical University of Munich (DE), Martin Luther University Halle-Wittenberg (DE), Technische Universität Dresden (DE), Charité - Universitätsmedizin Berlin (DE)
Openalex Percentile: Top 69%
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.